Feature | March 29, 2012

TAVI Study Shows Low Mortality, Improved Function at 30 Days

International multicenter ADVANCE study examines outcomes of TAVI at experienced centers

March 29, 2012 — Patients who underwent transcatheter aortic valve implantation (TAVI) at experienced medical centers had significant improvement in valve function as well as low mortality and stroke rates at 30 days, according to research presented this week at the American College of Cardiology (ACC) Annual Scientific Session.

The TAVI procedure includes inserting a bioprosthetic valve through a catheter and implanting it into a diseased native aortic valve. Because it is less invasive than surgical replacement, TAVI has been used for patients with a diseased aortic valve who cannot undergo surgery because of age, left ventricular dysfunction or the presence of coexisting conditions.

The ADVANCE study follows several trials already conducted to determine the safety and effectiveness of TAVI; however, it is the first large TAVI trial to use the Valve Academic Research Consortium’s (VARC) standards to define adverse events. It also used 44 centers that had each performed at least 40 TAVI procedures before joining the trial.

“This study evaluated real-world patients in everyday practice, allowing us to better understand the outcomes of typical use of TAVI,” said lead study author Axel Linke, professor of cardiology at the University of Leipzig Heart Center in Leipzig, Germany. “In addition, this study is one of the most rigorous TAVI studies ever conducted, and it is the first, large multicenter TAVI trial to report findings according to the new standard of evaluation, VARC.”

Between March 2010 and July 2011, a total of 1,015 high-risk patients with severe aortic stenosis were enrolled at 44 centers in 12 countries in Western Europe, Asia and South America. The patients’ mean age was 81 ± six years and 51 percent were female. The patients underwent TAVI and received the CoreValve System. They were then followed to determine the safety and efficacy of the procedure.

The study’s primary endpoint was the occurrence of major adverse cardiac and cerebrovascular events (MACCE), which is a composite of total death, stroke, heart attack and emergent cardiac surgery or percutaneous reintervention. The efficacy of the procedure was also analyzed by measuring valve function.

At the 30-day follow-up point, the researchers found that MACCE occurred in 8.3 percent of patients. The rates of total mortality and cardiac mortality were 4.5 percent and 2.2 percent, respectively, and the stroke rate was 2.9 percent. Life-threatening or disabling bleeding was observed in 4 percent of patients. The research team also found a persistent improvement in aortic valve function, accompanied by a better exercise capacity.

“The study’s conclusion is straightforward — that TAVI is effective and is associated with low mortality in the presence of an improvement in symptoms,” said Linke. “We included patients that were considered high operative risk and non-operable, and they definitely showed symptom improvement. The procedure provided great relief for the patients, as they did much better after implantation.”

The study was funded by Medtronic Inc. Linke disclosed that he is a consultant to Medtronic.

For more information: www.acc.org

Related Content

coherex Wave Crest LAA Occluder

Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System.

News | November 24, 2015
November 24, 2015 — Biosense Webster announced it has acquired Coherex Medical Inc., a privately held medical device
News | Heart Valve Repair| November 23, 2015
NaviGate Cardiac Structures Inc. (NCSI) announced that a first-in-human implant of its catheter-guided, mitral-valved...
Boston Scientific, Watchman FLX, LAA closure device, CE mark, first European implants

Image courtesy of Boston Scientific

News | Left Atrial Appendage (LAA) Occluders| November 20, 2015
Boston Scientific announced the first implants of the Watchman FLX left atrial appendage closure (LAAC) device
protein reprogramming, Stem Cells Translational Medicine, cardiac progenitor cells, CPCs, regenerative therapies
News | Stem Cell Therapies| November 13, 2015
A new study appearing in STEM CELLS Translational Medicine (SCTM) describes a highly efficient, protein-based method...
angina, abnormal heart blood flow, female-pattern heart disease, Cedars-Sinai Heart Institute study, AHA Scientific Sessions
News | Cardiac Diagnostics| November 13, 2015
Chest pain in female-pattern heart disease is linked with abnormal heart blood flow, a new Cedars-Sinai Heart Institute...
News | Antiplatelet and Anticoagulation Therapies| November 12, 2015
Preventing blood clots with drugs such as heparin has become a common practice for fighting some heart and lung...
pharmacist-physician collaboration, high blood pressure control, minority and low-income populations
News | Hypertension| November 12, 2015
November 12, 2015 — A pharmacist-physician collaborative effort to control blood pressure among a diverse group of pa
Neovasc, Tiara, transcatheter mitral valve, TMVR

The Neovasc Tiara transcatheter mitral valve is currently being tested in U.S. and international clinical trials. 

Feature | Heart Valve Repair| November 12, 2015 | Dave Fornell
The advent of transcatheter valve repair and replacement technologies is one of those rare instances where there is a
obese kids, eight years old, heart disease, MRI, Linyuan Jing
News | Cardiac Diagnostics| November 11, 2015
Imaging tests of obese children — some as young as 8 years old — showed signs of significant heart disease and heart...
Pradaxa, warfarin, safety and effectiveness, NVAF, non-valvular atrial fibrillation, clinical trial, AHA Scientific Sessions
News | Antiplatelet and Anticoagulation Therapies| November 11, 2015
Brigham and Women’s Hospital in Boston and Boehringer Ingelheim announced the results of a new interim analysis from a...
Overlay Init